Total submissions: 16
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000130643 | SCV000185522 | likely benign | Hereditary cancer-predisposing syndrome | 2021-04-10 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Gene |
RCV000656744 | SCV000209566 | uncertain significance | not provided | 2022-12-18 | criteria provided, single submitter | clinical testing | Observed in individuals with a personal history of colorectal adenomas, breast cancer, or other cancers (Azzopardi et al., 2008; Minde et al., 2011; Zhang et al., 2015; Ballinger et al., 2016; Rummel et al., 2017); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; In silico analysis is inconclusive as to whether the variant alters gene splicing. In the absence of RNA/functional studies, the actual effect of this sequence change is unknown.; This variant is associated with the following publications: (PMID: 25637381, 21859464, 18199528, 26580448, 27498913, 28152038, 28503720, 16454848, 12070164, 27535533, 11257105, 34301788) |
Invitae | RCV000206082 | SCV000260480 | uncertain significance | Familial adenomatous polyposis 1 | 2024-01-16 | criteria provided, single submitter | clinical testing | This sequence change replaces lysine, which is basic and polar, with arginine, which is basic and polar, at codon 150 of the APC protein (p.Lys150Arg). This variant is present in population databases (rs371085910, gnomAD 0.005%). This missense change has been observed in individual(s) with clinical features of familial adenomatous polyposis (PMID: 18199528). ClinVar contains an entry for this variant (Variation ID: 141928). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt APC protein function with a negative predictive value of 95%. RNA analysis performed to evaluate the impact of this missense change on mRNA splicing indicates it does not significantly alter splicing (Invitae). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Color Diagnostics, |
RCV000130643 | SCV000686977 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-12-11 | criteria provided, single submitter | clinical testing | This missense variant replaces lysine with arginine at codon 150 of the APC protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, protein functional studies have not been performed for this variant. This variant has been reported in individuals affected with breast cancer, colorectal adenomas, and rhabdosarcoma in the literature (PMID: 18199528, 21859464, 26580448, 28503720). This variant has been identified in 6/279048 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
Laboratory for Molecular Medicine, |
RCV000211892 | SCV000711457 | uncertain significance | not specified | 2020-05-22 | criteria provided, single submitter | clinical testing | proposed classification - variant undergoing re-assessment, contact laboratory |
Counsyl | RCV000206082 | SCV000785842 | uncertain significance | Familial adenomatous polyposis 1 | 2017-12-18 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV000656744 | SCV000805411 | uncertain significance | not provided | 2017-10-18 | criteria provided, single submitter | clinical testing | |
St. |
RCV000206082 | SCV000890906 | uncertain significance | Familial adenomatous polyposis 1 | 2021-08-03 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000211892 | SCV000918433 | uncertain significance | not specified | 2018-03-23 | criteria provided, single submitter | clinical testing | Variant summary: APC c.449A>G (p.Lys150Arg) results in a conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 2.2e-05 in 273686 control chromosomes. This frequency is not higher than expected for a pathogenic variant in APC causing Familial Adenomatous Polyposis (2.2e-05 vs 7.1e-05), allowing no conclusion about variant significance. c.449A>G has been reported in the literature in individuals affected with breast cancer and colon colorectal adenomas (Azzopardi_2008, Rummel_2017). These reports do not provide unequivocal conclusions about an association of the variant with Familial Adenomatous Polyposis. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. |
Sema4, |
RCV000130643 | SCV002534305 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-11-01 | criteria provided, single submitter | curation | |
Center for Genomic Medicine, |
RCV000211892 | SCV002550563 | likely benign | not specified | 2024-07-31 | criteria provided, single submitter | clinical testing | |
Myriad Genetics, |
RCV000206082 | SCV004018476 | likely benign | Familial adenomatous polyposis 1 | 2023-02-17 | criteria provided, single submitter | clinical testing | This variant is considered likely benign. This variant has been observed in conjunction with multiple pathogenic variants, reducing the likelihood this variant itself is pathogenic. |
Baylor Genetics | RCV000206082 | SCV004200933 | uncertain significance | Familial adenomatous polyposis 1 | 2024-03-27 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV003998072 | SCV004837273 | uncertain significance | Classic or attenuated familial adenomatous polyposis | 2024-02-05 | criteria provided, single submitter | clinical testing | This missense variant replaces lysine with arginine at codon 150 of the APC protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, protein functional studies have not been performed for this variant. This variant has been reported in individuals affected with breast cancer, colorectal adenomas, and rhabdosarcoma in the literature (PMID: 18199528, 21859464, 26580448, 28503720). This variant has been identified in 6/279048 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
CSER _CC_NCGL, |
RCV000148370 | SCV000190062 | uncertain significance | Colorectal adenoma | 2014-06-01 | no assertion criteria provided | research | |
True Health Diagnostics | RCV000130643 | SCV000693483 | uncertain significance | Hereditary cancer-predisposing syndrome | 2017-09-25 | no assertion criteria provided | clinical testing |